Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo 187-8502, Japan; Department of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.
Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo 187-8502, Japan; Translational Medical Center, National Center of Neurology and Psychiatry, Tokyo 187-8551, Japan.
J Affect Disord. 2018 Jan 15;226:155-162. doi: 10.1016/j.jad.2017.09.035. Epub 2017 Sep 27.
D-serine is an endogenous co-agonist of N-methyl-D-aspartate receptor (NMDAR) and plays an important role in glutamate neurotransmission. Several studies suggested the possible involvement of D-serine related in the pathophysiology of psychiatric disorders including major depression disorders (MDD). We tried to examine whether cerebrospinal fluid (CSF) or plasma D-serine concentrations are altered in MDD and whether D-serine concentrations correlated with disease severity.
26 MDD patients and 27 healthy controls matched for age, sex and ethnicity were enrolled. We measured amino acids in these samples using by high-performance liquid chromatography with fluorometric detection.
D-serine and L-serine, precursor of D-serine, levels in CSF or plasma were not significantly different in patients of MDD compared to controls. Furthermore, a significant correlation between D-serine levels in CSF and Hamilton Depression Rating Scale (HAMD)-17 score was observed (r = -0.65, p = 0.006). Furthermore, we found a positive correlation between CSF D-serine and HVA concentrations in MDD patients (r = 0.54, p = 0.007). CSF D-serine concentrations were correlated with those of plasma in MDD (r = 0.61, p = 0.01) but not in controls. In CSF, we also confirmed a significant correlation between D-serine and L-serine levels in MDD (r = 0.72, p < 0.0001) and controls (r = 0.70, p < 0.0001).
The study has some limitations; sample size was relatively small and most patients were medicated. We revealed that CSF D-serine concentrations were correlated with depression severity and HVA concentrations and further investigation were required to reveal the effect of medication and disease heterogeneity.
D-丝氨酸是 N-甲基-D-天冬氨酸受体(NMDAR)的内源性共激动剂,在谷氨酸能神经传递中发挥重要作用。几项研究表明,D-丝氨酸可能与包括重度抑郁症(MDD)在内的精神疾病的病理生理学有关。我们试图研究 MDD 患者的脑脊液(CSF)或血浆 D-丝氨酸浓度是否发生改变,以及 D-丝氨酸浓度是否与疾病严重程度相关。
纳入 26 名 MDD 患者和 27 名年龄、性别和种族相匹配的健康对照者。我们使用高效液相色谱法结合荧光检测法测定这些样本中的氨基酸。
与对照组相比,MDD 患者的 CSF 或血浆中的 D-丝氨酸和 D-丝氨酸前体 L-丝氨酸水平没有显著差异。此外,CSF 中 D-丝氨酸水平与汉密尔顿抑郁量表(HAMD)-17 评分呈显著负相关(r = -0.65,p = 0.006)。此外,我们发现 MDD 患者 CSF 中 D-丝氨酸与 HVA 浓度呈正相关(r = 0.54,p = 0.007)。MDD 患者的 CSF D-丝氨酸浓度与血浆呈正相关(r = 0.61,p = 0.01),但在对照组中无相关性。在 CSF 中,我们还证实了 MDD 患者和对照组中 D-丝氨酸和 L-丝氨酸水平之间存在显著相关性(r = 0.72,p < 0.0001;r = 0.70,p < 0.0001)。
该研究存在一些局限性;样本量相对较小,大多数患者正在接受药物治疗。我们发现 CSF D-丝氨酸浓度与抑郁严重程度和 HVA 浓度相关,需要进一步研究以揭示药物治疗和疾病异质性的影响。